China Gingko Crackdown Reveals Broad Quality Problems
This article was originally published in PharmAsia News
Amid another drug quality scare, this time involving Gingko extract products, the China FDA has worked through a holiday weekend to name and shame the good, the bad and the ugly. And in a revealing move, the agency has disclosed an unusually high number of bad apples.
You may also be interested in...
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.